Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Single-Blind, Randomized Study of Safety and Immunogenicity Following Vaccination With Single or Double Doses of HEPLISAV in Adults With End-Stage Renal Disease

Next Previous
X
Search
Trial Profile

A Phase 2, Single-Blind, Randomized Study of Safety and Immunogenicity Following Vaccination With Single or Double Doses of HEPLISAV in Adults With End-Stage Renal Disease

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 06 Mar 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adjuvanted Hepatitis-B vaccine (Recombinant)-Dynavax (Primary)
  • Indications Hepatitis B
  • Focus Adverse reactions
  • Sponsors Dynavax Technologies

    • Most Recent Events

    • 14 Apr 2010 Results presented in a poster session at the National Kidney Foundation Spring Clinical Meeting, as reported by Dynavax Technologies.
    • 21 Apr 2008 Added Dynavax Technologies as a sponsor (from ClinicalTrials.gov).
    • 21 Apr 2008 Status changed from suspended to discontinued. According to ClinicalTrials.gov, this study is on clinical hold.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top